2024-09-29-PitchBook-2024年二季度制药技术报告（英）_13页_7mb

Q2 2024 Pharmatech Report Summary

Overview

This summary covers the Q2 2024 analysis of the Pharmatech sector, including venture capital (VC) and private equity (PE) activity, key market events, innovation trends, and company highlights. The full report is confidential and available via the PitchBook Platform.

VC and PE Activity Overview

• Q2 2024 saw total VC funding of $1.1 billion across 48 deals, a slight decrease from Q1's $1.0 billion across 65 deals, reflecting a focus on larger-scale investments and strategic partnerships despite reduced transaction volume. Notable deals include Formation Bio's $372 million Series D and Delfi Diagnostics' $100 million Series B, highlighting investor confidence in late-stage companies.
• PE activity recorded 21 buyouts and nine growth equity transactions in the first half of 2024, continuing a downward trend with overall deal value decreasing by 43.5% year-over-year. Key exits include Gerresheimer's $861.7 million acquisition of Bormioli Pharma, underscoring interest in manufacturing and specialized pharma assets.
• Growth in AI-driven drug discovery platforms, such as XtalPi's IPO, showed moderate quarter-over-quarter growth in certain segments, but early-stage VC deals were less prominent due to lower investment compared to peak periods.

Key Events in Q2 2024

• Corporate Actions:
  • June 26: Formation Bio raises $372 million in Series D, valuing the company at $1.7 billion, led by Andreessen Horowitz for AI-accelerated drug development.
  • June 3: Delfi Diagnostics secures $100 million for early cancer detection technologies in Series B.
  • May 22: Gerresheimer AG acquires Bormioli Pharma for $861.7 million to strengthen primary packaging solutions.
  • June 5: Inventia Healthcare is bought out for $300 million by Platinum Equity for advanced oral drug delivery tech.
• IP and Deal Highlights:
  • June 13: XtalPi completes IPO raising $126.7 million.
  • May 2: Karius raises $100 million Series C for nucleic acid-based diagnostics.
• Transaction Trends:
  • VC deal count dropped to 48 from Q1's 65, but deal value remained steady at $1.1 billion, indicating a shift toward larger acquisitions.

Innovation Highlights

• AI and precision medicine dominate innovation, with CROs like Formation Bio leveraging AI for drug development and partnerships.
• Cell and gene therapy CDMOs are expanding, supported by investments in biologics and nucleic acid therapies, driven by increasing demand for targeted treatments.
• Market segments show VC activity concentrated in CDMO and CRO services, with early-stage investments in bioanalytics and vaccine tech.

Company Spotlight: AmplifyBio

• Founded in 2021, AmplifyBio is a CDMO specializing in preclinical testing and manufacturing for cell & gene therapies, with a broad focus on safety and efficacy studies.
• Key investors include Altimeter Capital, Insight Partners, and Casdin Capital; recent funding of $200 million supports expansion in vaccine technologies, biologics, and partnerships with entities like Battelle and the National Institutes of Health.
• Strategies involve balancing end-to-end biotech solutions to compete against specialists, with high potential for IPO success through innovation in therapy development.

Conclusion

The Q2 2024 Pharmatech sector shows a mixed landscape, with VC activity slowing but PE-driven deals increasing in strategic areas like manufacturing and AI. Innovations in precision medicine and gene therapies are key drivers, supported by exits and funding inflows indicating sustained industry interest.